Skip to main content

Table 1 213Bi-DOTATATE toxicity study in nontumor-bearing animals with or without pre-injection of l-lysine (35 mg), n = 8/cohort

From: Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine

MTD study in nontumor-bearing animals in combination with l-lysine

Cohort

213Bi-DOTATATE (MBq)

l-lysine

Days of injection

Low-dose(−)

13.0 ± 1.6

−

2

Low-dose(+)

13.2 ± 0.9

+

2

Medium-dose(−)

20.7 ± 0.8

−

3

Medium-dose(+)

21.7 ± 1.9

+

3

High-dose(−)

28.7 ± 1.2

−

4

High-dose(+)

28.3 ± 0.8

+

4

Control

0

 

4

  1. MTD maximum tolerated dose
  2. Control animals received 4 × 0.3 nmol DOTATATE (n = 8)